Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPR for Pediatric PTLD
NCT00066469Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Apr 2004
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Post-transplant lymphoproliferative disease (PTLD), sponsored by Children's Oncology Group. Primary endpoint: Event-free Survival at 2 years. Started Apr 2004; status: completed.
02
Drugs
rituximab
03
Conditions
Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT00066469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066469.